Jiangshi Pharma

Jiangshi Pharma (also known as Artisan Stone Pharma) is a Beijing-based biotechnology company specializing in the discovery and development of innovative small molecule drugs using targeted protein degradation (TPD) technologies. Founded in 2020 by industry veterans with experience at Pfizer and AbbVie, the company leverages its proprietary platform to develop Proteolysis-Targeting Chimeras (PROTACs) and molecular glues for previously "undruggable" targets. The company's research is particularly focused on identifying novel E3 ligase ligands to expand the therapeutic potential of protein degradation in oncology and immunology. Jiangshi Pharma has secured significant backing from prominent venture capital firms, including IDG Capital, Matrix Partners China, and Qiming Venture Partners. Currently in the pre-clinical stage, the company is advancing a pipeline of degraders targeting proteins such as STAT3 and BTK to address high unmet medical needs in cancer and autoimmune disorders.